Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2019 16:05 ET | Source: Novavax, Inc.

Novavax Reports Third Quarter 2019 Financial Results

NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. ...
October 31, 2019 16:05 ET | Source: Novavax, Inc.

Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019

GAITHERSBURG, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
October 15, 2019 07:00 ET | Source: Novavax, Inc.

Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of...
September 19, 2019 07:00 ET | Source: Novavax, Inc.

Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference

GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
September 06, 2019 07:00 ET | Source: Novavax, Inc.

Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
August 12, 2019 07:00 ET | Source: Novavax, Inc.

New Data from Novavax Phase 3 Prepare™ Trial of ResVax™ Presented at 2019 IDSOG Annual Meeting

GAITHERSBURG, Md., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
August 08, 2019 07:00 ET | Source: Novavax, Inc.

Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting

GAITHERSBURG, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
August 07, 2019 16:05 ET | Source: Novavax, Inc.

Novavax Reports Second Quarter 2019 Financial Results

Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with top-line data in...
August 05, 2019 16:05 ET | Source: Novavax, Inc.

Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFlu

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
August 01, 2019 09:25 ET | Source: Novavax, Inc.

Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 7, 2019

Gaithersburg, Md., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right